HomeCompareREVBU vs QYLD

REVBU vs QYLD: Dividend Comparison 2026

REVBU yields 690.37% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REVBU wins by $810427.05M in total portfolio value
10 years
REVBU
REVBU
● Live price
690.37%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$810427.07M
Annual income
$630,711,075,666.81
Full REVBU calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — REVBU vs QYLD

📍 REVBU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREVBUQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REVBU + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
REVBU pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REVBU
Annual income on $10K today (after 15% tax)
$58,681.39/yr
After 10yr DRIP, annual income (after tax)
$536,104,414,316.79/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, REVBU beats the other by $536,104,409,506.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REVBU + QYLD for your $10,000?

REVBU: 50%QYLD: 50%
100% QYLD50/50100% REVBU
Portfolio after 10yr
$405213.55M
Annual income
$315,355,540,663.07/yr
Blended yield
77.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on REVBU right now

REVBU
Analyst Ratings
1
Buy
Consensus: Buy
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REVBU buys
0
QYLD buys
0
No recent congressional trades found for REVBU or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREVBUQYLD
Forward yield690.37%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$810427.07M$25.4K
Annual income after 10y$630,711,075,666.81$5,659.31
Total dividends collected$795837.92M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: REVBU vs QYLD ($10,000, DRIP)

YearREVBU PortfolioREVBU Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$79,737$69,036.93$10,352$1,192.36+$69.4KREVBU
2$599,785$514,466.69$10,830$1,347.57+$589.0KREVBU
3$4,258,447$3,616,676.77$11,460$1,539.07+$4.25MREVBU
4$28,554,890$23,998,351.37$12,275$1,777.84+$28.54MREVBU
5$180,946,473$150,392,741.11$13,323$2,078.95+$180.93MREVBU
6$1,084,274,338$890,661,611.68$14,667$2,463.34+$1084.26MREVBU
7$6,148,076,706$4,987,903,165.00$16,396$2,960.57+$6148.06MREVBU
8$33,010,704,292$26,432,262,216.06$18,631$3,612.97+$33010.69MREVBU
9$167,958,874,690$132,637,421,097.63$21,548$4,482.15+$167958.85MREVBU
10$810,427,071,585$630,711,075,666.81$25,398$5,659.31+$810427.05MREVBU

REVBU vs QYLD: Complete Analysis 2026

REVBUStock

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Full REVBU Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this REVBU vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REVBU vs SCHDREVBU vs JEPIREVBU vs OREVBU vs KOREVBU vs MAINREVBU vs XYLDREVBU vs JEPQREVBU vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.